Skip to content

Intensive Cancer Screening After Cryptogenic Stroke

Occult Cancer

The INCOGNITO Pilot Trial is a single centre pilot prospective randomized open-label blinded endpoint (PROBE) trial to assess the feasibility of a full-scale randomized trial to determine whether an occult cancer screening strategy of FDG PET/CT in addition to usual care increases the number of occult cancers diagnosed after screening compared to usual care cancer screening alone in patients with cryptogenic stroke.

null

Conditions de participation

  • Sexe:

    ALL

  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:

* adults ≥18 years
* presenting to the Ottawa Hospital Stroke Prevention Clinic or the Ottawa Hospital Neurovascular Unit with a first cryptogenic ischemic stroke after advanced evaluation as per American Heart Association guidelines and Saver approach (maximum 3 months after stroke)
* patient or delegate willing and able to provide informed consent.

Exclusion Criteria:

* contraindications to FDG PET/CT (pregnancy or unable to lie still in bed for 20 minutes)
* active cancer or previous cancer diagnosis (other than basal or squamous cell carcinoma of the skin)

Lieu de l'étude

The Ottawa Hospital
The Ottawa Hospital
Ottawa, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Michele Demetroff

[email protected]
6137985555
Étude parrainée par
Ottawa Hospital Research Institute
Participants recherchés
Plus d'informations
ID de l'étude: NCT05733416